Press Releases

Date Title and Summary
Toggle Summary Accuray Incorporated Reports Inducement Grant Under NASDAQ Listing Rules
SUNNYVALE, Calif. , Oct. 4, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, an equity inducement award to Shig Hamamatsu , the company's new VP, Finance & Chief Accounting Officer. As a material inducement to Mr.
Toggle Summary 10-year Data Shows CyberKnife® System Provides Excellent Long-term Control of Low-Risk Prostate Cancer
First Study to Evaluate the Use of Stereotactic Body Radiation Therapy in Low-Risk Prostate Cancer 10 Years Post Treatment SUNNYVALE, Calif. , Sept. 26, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective study of 230 men with low-risk prostate
Toggle Summary Accuray Showcases CyberKnife® and Radixact™ Systems at ASTRO 2017
SUNNYVALE, Calif. , Sept. 20, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that data and first-hand experience with its advanced CyberKnife® and Radixact™ Systems , and unique software solutions, will be shared by leading radiation oncology practitioners at the 2017
Toggle Summary Accuray Reports Fourth Quarter and Fiscal 2017 Financial Results
SUNNYVALE, Calif. , Aug. 22, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2017 . Q4 Fiscal 2017 and Recent Highlights Gross orders of $85.7 million driven by strong demand from both the new Radixact
Toggle Summary Summit Cancer Center-Boise Treats Its First Cancer Patients Using the Accuray Radixact™ System
Freestanding Center is First in the Western U.S. to Treat Patients with this "Smart" Radiation Therapy Delivery System with Fully-Integrated Treatment Planning and Data Management Systems SUNNYVALE, Calif. , Aug. 17, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) and the Summit Cancer
Toggle Summary Accuray To Report Fiscal 2017 Fourth Quarter And Full Year Results On August 22, 2017
SUNNYVALE, Calif. , Aug. 14, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2017 ended June 30, 2017 on Tuesday, August 22, 2017 after the market close. Management will host a conference call to review the results at 1:30 p.m.
Toggle Summary First Radixact™ System Research Results Presented at the American Association of Physicists in Medicine Annual Meeting
SUNNYVALE, Calif. , Aug. 4, 2017 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that the first studies validating the benefits of the leading-edge Radixact™ System were presented at the 59th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in
Toggle Summary Accuray Receives 510(k) Clearance for iDMS™ Data Management System Upgrade for the TomoTherapy® System
iDMS System Allows Seamless Integration between Accuray Radixact™, TomoTherapy® and CyberKnife® Systems and Treatment Planning Systems SUNNYVALE, Calif. , July 31, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today it has received 510(k) clearance from the U.S.
Toggle Summary Accuray Enhances Capital Structure Through Convertible Debt Transactions
­Transactions Facilitate Reduction of Short-term Debt and Potential Dilution to Shareholders SUNNYVALE, Calif. , July 28, 2017 /PRNewswire/ -- Accuray Incorporated  (NASDAQ: ARAY) has entered into privately negotiated agreements with a limited number of existing holders of the company's outstanding
Toggle Summary New Data Show TomoTherapy® System Superior to RapidArc in Achieving Local Control of Head and Neck Cancers
Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function SUNNYVALE, Calif.